

REMARKS

This is in response to the Official Action of March 9, 2004. The points raised therein are addressed below in the order originally set forth.

Drawings. A corrected drawing is submitted concurrently herewith. The drawing is corrected herein to illustrate items #21 and #22 in Figure 3 and to make the drawing consistent with the description in the specification.

Specification. The specification is amended herein to incorporate Sequenced Listing identification numbers to all nucleotide sequences in the specification and to update the first paragraph to reflect the current parent application data. Withdrawal of the objections to the specification is respectfully requested.

Title. The title has been amended to be consistent with the new title suggested by the Examiner, and withdrawal of this rejection is respectfully requested.

Claim rejections, 35 U.S.C. § 112. Claim 138 (and 140–142 dependent thereon) stands rejected as indefinite in the use of "said different oligonucleotide capture probes." The claim has been amended to clarify usage of the oligonucleotide capture probes throughout, and withdrawal of this rejection is respectfully requested.

Notice to comply with nucleic acid sequence rules. A response to the notice to comply with nucleic acid sequence rules is submitted concurrently herewith. Included with this response is a Sequence Listing in computer-readable form, a paper copy thereof and a statement that the contents of the computer-readable and paper copies of the Sequence Listing are the same.

Attorney Docket No. 5470-107BDV3

Application Serial No. 10/008,233

Filed: November 6, 2001

Page 9 of 9

It is respectfully submitted that this application is in condition for allowance, which action is respectfully requested.

Respectfully submitted,



Kenneth D. Sibley

Registration No. 31,665

USPTO Customer No. 20792
Myers Bigel Sibley & Sajovec, P.A.
Post Office Box 37428
Raleigh, North Carolina 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401